Related Experiment Video
Updated: Jul 9, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
[Experimental siCD44-targeted therapy of human nasopharyngeal carcinoma mediated by adenovirus]
Ji-yu Jod1, Yan Shi, Yi-qun Zhou
1Department of Immunology, Institute of Basic Medical Sciences, CAMS and PUMC, Beijing 100005, China.
Objective:
To explore the possibility of treating solid tumor with siCD44.
Methods:
Human nasopharyngeal carcinoma cell CNE-2L2 with high expression of CD44 was used in this study. The malignant activities of cells were examined by colony formation test, tumorigenesis, and lung metastasis of the tumor in nude mice. Ad5-siCD44 was constructed and adenoviruses were produced in 293 cells. CNE-2L2 cells were subcutaneously inoculated into nude mice. When tumors grew to 50-100 mm3, Ad5-siCD44 was injected into tumors, and Ad5-egfp and PBS were also injected as controls. The size and weight of tumors were compared after 2 weeks.
Results:
Suppression of CD44 expression profoundly inhibited the malignant activities of CNE-2L2 cell. The average sizes of the tumors were (3.139 +/- 0.850), (3.612 +/- 0.888), and (1.512 +/- 0.742) cm3 after the intra-tumor injection of PBS, Ad5-egfp, and Ad5-siCD44, respectively, after two weeks. Significant difference was found between Ad5-siCD44 group and control groups (P < 0.05). The average weights were (2.28 +/- 0.73), (1.83 +/- 0.26), and (1.20 +/- 0.64) g, respectively, and significant difference was also found between Ad5-siCD44 group and control groups (P < 0.05).
Conclusion:
Intra-tumor injection of Ad5-siCD44 can exhibit the therapeutic effect on the tumor inoculated with CNE-2L2 cells with high expression of CD44 in nude mice.
Insights
Intra-tumor injection of Ad5-siCD44 significantly reduced tumor size and weight in mice. This study explored siCD44 as a potential treatment for solid tumors expressing CD44.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- CD44 is a cell surface glycoprotein implicated in tumor progression and metastasis.
- Targeting CD44 offers a potential therapeutic strategy for solid tumors.
Purpose of the Study:
- To investigate the efficacy of small interfering RNA targeting CD44 (siCD44) delivered via adenovirus (Ad5-siCD44) in treating solid tumors.
- To evaluate the impact of CD44 suppression on the malignant activities of nasopharyngeal carcinoma cells.
Main Methods:
- Human nasopharyngeal carcinoma CNE-2L2 cells with high CD44 expression were used.
- Malignant activities were assessed through colony formation, tumorigenesis, and lung metastasis assays in nude mice.
- Ad5-siCD44 was administered via intratumoral injection, with PBS and Ad5-egfp as controls.
Main Results:
- Suppression of CD44 expression significantly inhibited CNE-2L2 cell malignant activities.
- Ad5-siCD44 treatment resulted in a significant reduction in tumor size and weight compared to control groups (P < 0.05).
- Average tumor sizes were 1.512 cm³ (Ad5-siCD44) vs. 3.139 cm³ (PBS) and 3.612 cm³ (Ad5-egfp).
Conclusions:
- Intratumoral delivery of Ad5-siCD44 demonstrates therapeutic potential against CD44-expressing solid tumors.
- siCD44 holds promise as a targeted therapy for nasopharyngeal carcinoma and potentially other CD44-positive cancers.
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...